2023
Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes
Ash G, Nally L, Stults-Kolehmainen M, De Los Santos M, Jeon S, Brandt C, Gulanski B, Spanakis E, Baker J, Weinzimer S, Fucito L. Personalized Digital Health Information to Substantiate Human-Delivered Exercise Support for Adults With Type 1 Diabetes. Clinical Journal Of Sport Medicine 2023, 33: 512-520. PMID: 36715983, PMCID: PMC10898917, DOI: 10.1097/jsm.0000000000001078.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringExercise supportHealth informationDigital health informationBody mass indexType 1 diabetesCommunity-based sampleSevere hypoglycemiaMass indexPsychosocial assessmentCGM useHigh satisfaction ratingsPhysician oversightType 1Future interventionsGlucose monitoringMedical readinessMolecular biomarkersBaseline observationsInterventionSatisfaction ratingsAdultsExerciseBehavioral skillsSingle group
2022
“It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes
Hughes A, Chapman K, Bispham J, Dimsits J, Weinzimer S, Wolf W, Heydarian N. “It’s embarrassing. I get angry. I get frustrated.”: Understanding severe hypoglycemia and glucagon usage from the perspectives of people with type 1 diabetes. Journal Of Clinical & Translational Endocrinology 2022, 30: 100310. PMID: 36620758, PMCID: PMC9816066, DOI: 10.1016/j.jcte.2022.100310.Peer-Reviewed Original ResearchSevere hypoglycemiaType 1 diabetesGlucagon useMini-dose glucagonEase of administrationPrescription costsNasal administrationEmergency treatmentGlucagon actionPerspectives of adultsHypoglycemiaDiabetesGlucagon treatmentHealthcare professionalsGlucagonAverage durationPerspectives of peopleAdministrationAdultsParticipantsFocus groupsTreatmentCurrent studyFocus group interviewsEmotional impactAssessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdults
2019
Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes
Danne T, Pettus J, Giaccari A, Cariou B, Rodbard H, Weinzimer S, Bonnemaire M, Sawhney S, Stewart J, Wang S, de Cassia Castro R, Garg S. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 471-477. PMID: 31335194, PMCID: PMC6708262, DOI: 10.1089/dia.2019.0157.Peer-Reviewed Original ResearchConceptsSotagliflozin 200Insulin therapyHypoglycemia eventsRate of hypoglycemiaType 1 diabetesLevel 2 hypoglycemiaLower ratesImportant hypoglycemiaHypoglycemia ratesWeek 52Adult patientsGlycemic controlHypoglycemic eventsHypoglycemic rateClinical trialsInsulin treatmentPlaceboSotagliflozinHypoglycemiaType 1Phase 3PatientsTherapyWeeksAdults
2017
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2016
Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance
Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA. Automated hybrid closed‐loop control with a proportional‐integral‐derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes 2016, 18: 348-355. PMID: 27191182, DOI: 10.1111/pedi.12399.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdolescentAdolescent BehaviorAdultAlgorithmsBlood GlucoseBlood Glucose Self-MonitoringCalibrationCohort StudiesDiabetes Mellitus, Type 1Drug Dosage CalculationsDrug MonitoringGlucoseHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsInsulinPancreas, ArtificialPrecision MedicineSubcutaneous TissueYoung AdultConceptsType 1 diabetesAdolescent cohortAdult cohortHybrid closed-loop systemPump therapyPercentage of timeGlucose valuesSensor-augmented pump therapyOverall glucose controlInsulin pump therapyOverall mean percentageDose insulinGlucose controlPreliminary safetyInsulin delivery systemsInitial cohortHybrid closed-loop controlClinical practiceSecond cohortCohortMean percentageTarget rangeOverall percentageDiabetesAdults
2009
Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Bode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.Peer-Reviewed Original Research